stocks logo

ATOS

Atossa Therapeutics Inc
$
0.850
+0.001(0.118%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.8594
Open
0.850
VWAP
0.85
Vol
247.17K
Mkt Cap
109.63M
Low
0.8401
Amount
210.98K
EV/EBITDA(TTM)
--
Total Shares
125.76M
EV
43.63M
EV/OCF(TTM)
--
P/S(TTM)
--
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
--
--
-0.060
+20%
--
--
-0.057
-5.55%
--
--
-0.057
+13.34%
Estimates Revision
The market is revising No Change the revenue expectations for Atossa Therapeutics, Inc. (ATOS) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 28.13%.
EPS Estimates for FY2025
Revise Downward
down Image
-8%
In Past 3 Month
Stock Price
Go Up
up Image
+28.13%
In Past 3 Month
4 Analyst Rating
up Image
562.35% Upside
Wall Street analysts forecast ATOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATOS is 5.63 USD with a low forecast of 4.00 USD and a high forecast of 7.50  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
up Image
562.35% Upside
Current: 0.850
sliders
Low
4.00
Averages
5.63
High
7.50
Craig-Hallum
NULL
to
Buy
initiated
$4
2025-06-05
Reason
Craig-Hallum initiated coverage of Atossa Therapeutics with a Buy rating and $4 price target.
Craig-Hallum
Craig-Hallum
Buy
initiated
$4
2025-06-05
Reason
As previously reported, Craig-Hallum initiated coverage of Atossa Therapeutics with a Buy rating and $4 price target. The firm points out that Z-endoxifen is a novel and potent SERM that can treat all stages of breast cancer. As the primary therapeutic metabolite of tamoxifen, Z-endoxifen is de-risked and has demonstrated differentiated efficacy and an advantageous safety profile in multiple clinical studies, Craig-Hallum argues, adding that Z-endoxifen development is focused on metastatic breast cancer, which offers the fastest path to market and can strategically support future expansion to early disease settings. The most notable opportunity is prevention, where Z-endoxifen's ability to avoid menopausal-like side effects can support uptake in a large TAM of over 10M women at high-risk of developing breast cancer in the U.S. The firm believes Atossa is undervalued and sees opportunity for share appreciation as Z-endoxifen gains further validation with readouts from neoadjuvant studies expected next year and design details for a Phase III metastatic breast cancer study and initiation expected by year-end 2025.
Ascendiant Capital
Edward Woo
Strong Buy
Maintains
$7 → $7.25
2025-04-21
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$7
2025-03-26
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$7
2025-03-12
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$7
2025-01-30
Reason

Valuation Metrics

The current forward P/E ratio for Atossa Therapeutics Inc (ATOS.O) is -3.61, compared to its 5-year average forward P/E of -6.42. For a more detailed relative valuation and DCF analysis to assess Atossa Therapeutics Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.42
Current PE
-3.61
Overvalued PE
-0.02
Undervalued PE
-12.82

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

Annual
Quarterly
FY2025Q1
YoY :
+6.22%
-7.41M
Operating Profit
FY2025Q1
YoY :
+14.29%
-6.72M
Net Income after Tax
FY2025Q1
YoY :
-0.00%
-0.05
EPS - Diluted
FY2025Q1
YoY :
+26.87%
-5.97M
Free Cash Flow

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
1
9.9K
USD
Months
3-6
1
7.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

ATOS News & Events

Events Timeline

2025-05-14 (ET)
2025-05-14
08:19:50
Atossa Therapeutics reports results from Phase 2 EOP sub-study
select
2025-04-30 (ET)
2025-04-30
08:46:36
Atossa Therapeutics announces issuance of U.S. patent for (Z)-endoxifen
select
2025-04-29 (ET)
2025-04-29
08:47:13
Atossa Therapeutics proposes study aimed at reducing interval breast cancer
select
Sign Up For More Events

News

4.0
06-06Benzinga
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $7.5
4.0
06-05Benzinga
This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
1.0
06-02Newsfilter
Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference
Sign Up For More News

FAQ

arrow icon

What is Atossa Therapeutics Inc (ATOS) stock price today?

The current price of ATOS is 0.85 USD — it has increased 0.12 % in the last trading day.

arrow icon

What is Atossa Therapeutics Inc (ATOS)'s business?

arrow icon

What is the price predicton of ATOS Stock?

arrow icon

What is Atossa Therapeutics Inc (ATOS)'s revenue for the last quarter?

arrow icon

What is Atossa Therapeutics Inc (ATOS)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Atossa Therapeutics Inc (ATOS)'s fundamentals?

arrow icon

How many employees does Atossa Therapeutics Inc (ATOS). have?

arrow icon

What is Atossa Therapeutics Inc (ATOS) market cap?